The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online
3D image of ovarian cancer

Cleo Diagnostics patents ovarian cancer test IP; shares jump on low liquidity

Ovarian cancer detection biotech Cleo Diagnostics (ASX: COV) has seen shares jump towards +4% on Wednesday as it patents
Exit sign

Paradigm Biopharma draws ire as administrators called in one week after suspension

Paradigm Biopharma (ASX:PAR) has made the sad move of calling in voluntary administrators on Wednesday after the latest data
Nasal spray

Firebrick Pharma flags intention to enter US market with nasal iodine product

Firebrick Pharma (ASX:FRE) has formally earmarked its ambitions to penetrate the US retail market with its Nasodine (nasal iodine)

AFT Pharmaceuticals opens Japan opportunity for Maxigesic IV

AFT Pharmaceuticals (ASX: AFP) has secured an exclusive development, licensing and supply agreement for its Maxigesic® IV (also known as Combogesic® IV)